Literature DB >> 20574730

Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer?

Takayoshi Uematsu1, Masako Kasami, Junichiro Watanabe, Kaoru Takahashi, Seiji Yamasaki, Kumiko Tanaka, Yukiko Tadokoro, Akiko Ogiya.   

Abstract

BACKGROUND: Patients who achieve pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) have favorable disease-free survival rates. A few studies have suggested that lymphovascular invasion degree may play an important role in predicting pCR. This study aims to confirm the role of lymphatic invasion degree in predicting pCR in breast cancer patients after NAC.
METHODS: We retrospectively analyzed 120 patients treated with NAC and surgery. The following pathological features were evaluated on surgical specimens after NAC: histological grade, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2), lymphovascular invasion degree, intratumoral necrosis positivity, and axillary lymph node positivity.
RESULTS: pCR and marked response were achieved in 12% (14/120) and 35% (42/120), respectively, of 120 breast cancers in 120 women. Breast cancers with pCR or marked response were classified as chemosensitive. The remaining 64 breast cancers (53%) were classified as chemoresistant. Severe lymphovascular invasion (P = .003), large tumor size (P = .029), ER positivity (P = .001), and PR positivity (P = .006) were significantly associated with chemoresistant breast cancer. Invasive ductal carcinoma (P = .028) and HER-2 positivity (P < .0001) were significantly associated with chemosensitive breast cancer. On multivariate analysis, HER-2 positivity (P < .0001), invasive ductal carcinoma (P = .047), and marked/moderate lymphovascular invasion (P = .023) were the three factors that remained statistically significant in the model to predict histological therapeutic effect.
CONCLUSION: Lymphovascular invasion degree is one of the important factors to predict NAC efficacy for breast cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20574730     DOI: 10.1007/s12282-010-0211-z

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  12 in total

1.  Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657).

Authors:  Elizabeth L Cureton; Christina Yau; Michael D Alvarado; Helen Krontiras; David W Ollila; Cheryl A Ewing; Sindy Monnier; Laura J Esserman
Journal:  Ann Surg Oncol       Date:  2014-05-01       Impact factor: 5.344

2.  FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients.

Authors:  Caroline Rousseau; Anne Devillers; Mario Campone; Loïc Campion; Ludovic Ferrer; Christine Sagan; Myriam Ricaud; Boumédiène Bridji; Françoise Kraeber-Bodéré
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-10       Impact factor: 9.236

3.  Development and validation of a nomogram based on pretreatment dynamic contrast-enhanced MRI for the prediction of pathologic response after neoadjuvant chemotherapy for triple-negative breast cancer.

Authors:  Yanbo Li; Yongzi Chen; Rui Zhao; Yu Ji; Junnan Li; Ying Zhang; Hong Lu
Journal:  Eur Radiol       Date:  2021-11-12       Impact factor: 7.034

4.  Correlation of Early Recurrence With In Vitro Adenosine Triphosphate Based Chemotherapy Response Assay in Pancreas Cancer With Postoperative Gemcitabine Chemotherapy.

Authors:  Joon Seong Park; Jae Keun Kim; Dong Sup Yoon
Journal:  J Clin Lab Anal       Date:  2016-03-17       Impact factor: 2.352

5.  Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy.

Authors:  Ying L Liu; Anurag Saraf; Shing M Lee; Xiaobo Zhong; Hanina Hibshoosh; Kevin Kalinsky; Eileen P Connolly
Journal:  Breast Cancer Res Treat       Date:  2016-05-25       Impact factor: 4.872

6.  Features from MRI texture analysis associated with survival outcomes in triple-negative breast cancer patients.

Authors:  Saki Kamiya; Hiroko Satake; Yoko Hayashi; Satoko Ishigaki; Rintaro Ito; Mariko Kawamura; Toshiaki Taoka; Shingo Iwano; Shinji Naganawa
Journal:  Breast Cancer       Date:  2021-09-16       Impact factor: 4.239

7.  Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients

Authors:  Pegah Sasanpour; Saleh Sandoughdaran; Alireza Mosavi-Jarrahi; Mona Malekzadeh
Journal:  Asian Pac J Cancer Prev       Date:  2018-09-26

8.  Lymphovascular invasion can be better than pathologic complete response to predict prognosis in breast cancer treated with neoadjuvant chemotherapy.

Authors:  Young Jae Ryu; Shin Jae Kang; Jin Seong Cho; Jung Han Yoon; Min Ho Park
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

9.  Nomogram-derived prediction of pathologic complete response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy (NCT).

Authors:  Shengyu Pu; Ke Wang; Yang Liu; Xiaoqin Liao; Heyan Chen; Jianjun He; Jian Zhang
Journal:  BMC Cancer       Date:  2020-11-19       Impact factor: 4.430

10.  Can We Reliably Identify the Pathological Outcomes of Neoadjuvant Chemotherapy in Patients with Breast Cancer? Development and Validation of a Logistic Regression Nomogram Based on Preoperative Factors.

Authors:  Jian Zhang; Linhai Xiao; Shengyu Pu; Yang Liu; Jianjun He; Ke Wang
Journal:  Ann Surg Oncol       Date:  2020-10-23       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.